These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 11303815)

  • 1. Pharmacokinetics of ceftazidime in febrile neutropenic patients.
    Nyhlén A; Ljungberg B; Nilsson-Ehle I
    Scand J Infect Dis; 2001; 33(3):222-6. PubMed ID: 11303815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections.
    Benko AS; Cappelletty DM; Kruse JA; Rybak MJ
    Antimicrob Agents Chemother; 1996 Mar; 40(3):691-5. PubMed ID: 8851594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuous infusion of ceftazidime in febrile neutropenic patients with acute myeloid leukemia.
    Daenen S; Erjavec Z; Uges DR; De Vries-Hospers HG; De Jonge P; Halie MR
    Eur J Clin Microbiol Infect Dis; 1995 Mar; 14(3):188-92. PubMed ID: 7614958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose continuous-infusion ceftazidime monotherapy in low-risk febrile neutropenic patients.
    Marshall E; Smith DB; O'Reilly SM; Murray A; Kelly V; Clark PI
    Support Care Cancer; 2000 May; 8(3):198-202. PubMed ID: 10789960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cefepime versus ceftazidime as empiric therapy for fever in neutropenic patients with cancer.
    Chandrasekar PH; Arnow PM
    Ann Pharmacother; 2000 Sep; 34(9):989-95. PubMed ID: 10981242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of ceftazidime in loggerhead sea turtles (Caretta caretta) after single intravenous and intramuscular injections.
    Stamper MA; Papich MG; Lewbart GA; May SB; Plummer DD; Stoskopf MK
    J Zoo Wildl Med; 1999 Mar; 30(1):32-5. PubMed ID: 10367641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ceftazidime pharmacokinetics in preterm infants: effects of renal function and gestational age.
    van den Anker JN; Schoemaker RC; Hop WC; van der Heijden BJ; Weber A; Sauer PJ; Neijens HJ; de Groot R
    Clin Pharmacol Ther; 1995 Dec; 58(6):650-9. PubMed ID: 8529330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once daily ceftriaxone plus amikacin vs. three times daily ceftazidime plus amikacin for treatment of febrile neutropenic children with cancer. Writing Committee for the International Collaboration on Antimicrobial Treatment of Febrile Neutropenia in Children.
    Charnas R; Lüthi AR; Ruch W
    Pediatr Infect Dis J; 1997 Apr; 16(4):346-53. PubMed ID: 9109134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clearance of ceftazidime during continuous venovenous haemofiltration in critically ill patients.
    Traunmüller F; Schenk P; Mittermeyer C; Thalhammer-Scherrer R; Ratheiser K; Thalhammer F
    J Antimicrob Chemother; 2002 Jan; 49(1):129-34. PubMed ID: 11751776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advancing age and acute infection influence the kinetics of ceftazidime.
    Ljungberg B; Nilsson-Ehle I
    Scand J Infect Dis; 1989; 21(3):327-32. PubMed ID: 2667099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once-daily versus twice-daily administration of ceftazidime in the preterm infant.
    van den Anker JN; Schoemaker RC; van der Heijden BJ; Broerse HM; Neijens HJ; de Groot R
    Antimicrob Agents Chemother; 1995 Sep; 39(9):2048-50. PubMed ID: 8540714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients.
    Hess U; Böhme C; Rey K; Senn HJ
    Support Care Cancer; 1998 Jul; 6(4):402-9. PubMed ID: 9695210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacokinetics of ceftazidime in lactating and non-lactating cows.
    Rule R; Quiroga GH; Rubio M; Buschiazzo HO; Buschiazzo PM
    Vet Res Commun; 1996; 20(6):543-50. PubMed ID: 8950835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of meropenem in febrile neutropenic patients. Swedish study group.
    Nyhlén A; Ljungberg B; Nilsson-Ehle I
    Eur J Clin Microbiol Infect Dis; 1997 Nov; 16(11):797-802. PubMed ID: 9447900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intermittent bolus dosing of ceftazidime in critically ill patients.
    Young RJ; Lipman J; Gin T; Gomersall CD; Joynt GM; Oh TE
    J Antimicrob Chemother; 1997 Aug; 40(2):269-73. PubMed ID: 9301994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections.
    McKinnon PS; Paladino JA; Schentag JJ
    Int J Antimicrob Agents; 2008 Apr; 31(4):345-51. PubMed ID: 18313273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered pharmacokinetics of ceftazidime in critically ill patients.
    Gómez CM; Cordingly JJ; Palazzo MG
    Antimicrob Agents Chemother; 1999 Jul; 43(7):1798-802. PubMed ID: 10390248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis.
    Angus BJ; Smith MD; Suputtamongkol Y; Mattie H; Walsh AL; Wuthiekanun V; Chaowagul W; White NJ
    Br J Clin Pharmacol; 2000 Aug; 50(2):184-91. PubMed ID: 10930972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: a randomized, double-blind trial.
    Feld R; DePauw B; Berman S; Keating A; Ho W
    J Clin Oncol; 2000 Nov; 18(21):3690-8. PubMed ID: 11054442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure.
    Pea F; Viale P; Damiani D; Pavan F; Cristini F; Fanin R; Furlanut M
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3550-3. PubMed ID: 16048982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.